300 related articles for article (PubMed ID: 26297272)
1. Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1.
Choi MY; Widhopf GF; Wu CC; Cui B; Lao F; Sadarangani A; Cavagnaro J; Prussak C; Carson DA; Jamieson C; Kipps TJ
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl(0):S167-9. PubMed ID: 26297272
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells.
Daneshmanesh AH; Hojjat-Farsangi M; Khan AS; Jeddi-Tehrani M; Akhondi MM; Bayat AA; Ghods R; Mahmoudi AR; Hadavi R; Österborg A; Shokri F; Rabbani H; Mellstedt H
Leukemia; 2012 Jun; 26(6):1348-55. PubMed ID: 22289919
[TBL] [Abstract][Full Text] [Related]
3. Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia.
Hojjat-Farsangi M; Jeddi-Tehrani M; Daneshmanesh AH; Mozaffari F; Moshfegh A; Hansson L; Razavi SM; Sharifian RA; Rabbani H; Österborg A; Mellstedt H; Shokri F
PLoS One; 2015; 10(11):e0142310. PubMed ID: 26562161
[TBL] [Abstract][Full Text] [Related]
4. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia.
Baskar S; Kwong KY; Hofer T; Levy JM; Kennedy MG; Lee E; Staudt LM; Wilson WH; Wiestner A; Rader C
Clin Cancer Res; 2008 Jan; 14(2):396-404. PubMed ID: 18223214
[TBL] [Abstract][Full Text] [Related]
5. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.
Hudecek M; Schmitt TM; Baskar S; Lupo-Stanghellini MT; Nishida T; Yamamoto TN; Bleakley M; Turtle CJ; Chang WC; Greisman HA; Wood B; Maloney DG; Jensen MC; Rader C; Riddell SR
Blood; 2010 Nov; 116(22):4532-41. PubMed ID: 20702778
[TBL] [Abstract][Full Text] [Related]
6.
Rassenti LZ; Balatti V; Ghia EM; Palamarchuk A; Tomasello L; Fadda P; Pekarsky Y; Widhopf GF; Kipps TJ; Croce CM
Proc Natl Acad Sci U S A; 2017 Oct; 114(40):10731-10736. PubMed ID: 28923920
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies.
Yang J; Baskar S; Kwong KY; Kennedy MG; Wiestner A; Rader C
PLoS One; 2011; 6(6):e21018. PubMed ID: 21698301
[TBL] [Abstract][Full Text] [Related]
8. ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.
Widhopf GF; Cui B; Ghia EM; Chen L; Messer K; Shen Z; Briggs SP; Croce CM; Kipps TJ
Proc Natl Acad Sci U S A; 2014 Jan; 111(2):793-8. PubMed ID: 24379361
[TBL] [Abstract][Full Text] [Related]
9. Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia.
Chen Y; Chen L; Yu J; Ghia EM; Choi MY; Zhang L; Zhang S; Sanchez-Lopez E; Widhopf GF; Messer K; Rassenti LZ; Jamieson C; Kipps TJ
Blood; 2019 Sep; 134(13):1084-1094. PubMed ID: 31409670
[TBL] [Abstract][Full Text] [Related]
10. Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia.
Choi MY; Widhopf GF; Ghia EM; Kidwell RL; Hasan MK; Yu J; Rassenti LZ; Chen L; Chen Y; Pittman E; Pu M; Messer K; Prussak CE; Castro JE; Jamieson C; Kipps TJ
Cell Stem Cell; 2018 Jun; 22(6):951-959.e3. PubMed ID: 29859176
[TBL] [Abstract][Full Text] [Related]
11. Use of the receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a diagnostic tool in chronic lymphocytic leukemia (CLL).
Uhrmacher S; Schmidt C; Erdfelder F; Poll-Wolbeck SJ; Gehrke I; Hallek M; Kreuzer KA
Leuk Res; 2011 Oct; 35(10):1360-6. PubMed ID: 21531460
[TBL] [Abstract][Full Text] [Related]
12. Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells.
Hasan MK; Yu J; Chen L; Cui B; Widhopf Ii GF; Rassenti L; Shen Z; Briggs SP; Kipps TJ
Leukemia; 2017 Dec; 31(12):2615-2622. PubMed ID: 28465529
[TBL] [Abstract][Full Text] [Related]
13. Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia.
Hasan MK; Yu J; Widhopf GF; Rassenti LZ; Chen L; Shen Z; Briggs SP; Neuberg DS; Kipps TJ
Blood; 2018 Jul; 132(2):170-178. PubMed ID: 29678828
[TBL] [Abstract][Full Text] [Related]
14. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation.
Yu J; Chen L; Cui B; Widhopf GF; Shen Z; Wu R; Zhang L; Zhang S; Briggs SP; Kipps TJ
J Clin Invest; 2016 Feb; 126(2):585-98. PubMed ID: 26690702
[TBL] [Abstract][Full Text] [Related]
15. Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells.
Hasan MK; Rassenti L; Widhopf GF; Yu J; Kipps TJ
Leukemia; 2019 Mar; 33(3):653-661. PubMed ID: 30568170
[TBL] [Abstract][Full Text] [Related]
16. The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells.
Hojjat-Farsangi M; Khan AS; Daneshmanesh AH; Moshfegh A; Sandin A; Mansouri L; Palma M; Lundin J; Österborg A; Mellstedt H
PLoS One; 2013; 8(10):e78339. PubMed ID: 24205204
[TBL] [Abstract][Full Text] [Related]
17. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J
Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100
[TBL] [Abstract][Full Text] [Related]
18. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy.
Zhang S; Cui B; Lai H; Liu G; Ghia EM; Widhopf GF; Zhang Z; Wu CC; Chen L; Wu R; Schwab R; Carson DA; Kipps TJ
Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17266-71. PubMed ID: 25411317
[TBL] [Abstract][Full Text] [Related]
19. Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy.
Daneshmanesh AH; Mikaelsson E; Jeddi-Tehrani M; Bayat AA; Ghods R; Ostadkarampour M; Akhondi M; Lagercrantz S; Larsson C; Osterborg A; Shokri F; Mellstedt H; Rabbani H
Int J Cancer; 2008 Sep; 123(5):1190-5. PubMed ID: 18546292
[TBL] [Abstract][Full Text] [Related]
20. The PI3K/AKT/mTOR pathway is involved in direct apoptosis of CLL cells induced by ROR1 monoclonal antibodies.
Daneshmanesh AH; Hojjat-Farsangi M; Moshfegh A; Khan AS; Mikaelsson E; Österborg A; Mellstedt H
Br J Haematol; 2015 May; 169(3):455-8. PubMed ID: 25407287
[No Abstract] [Full Text] [Related]
[Next] [New Search]
